 |
A. J. Kazimi, is Chief Executive Officer and Chairman of the Board of Directors at CET. Previously, Mr. Kazimi helped guide and build the international biopharmaceutical company Therapeutic Antibodies Inc. As President and Chief Operating Officer, he made key contributions to the company’s growth through its IPO and initial product launches, including oversight of operations in three countries, closing more than $30 million in product agreements, and steering the company through debt and equity financings totaling more than $100 million. At Brown-Forman Corporation, Mr. Kazimi held a series of management positions and was involved in launching several new products. Mr. Kazimi serves on the board of directors for the Nashville Health Care Council, an industry association representing the largest concentration of healthcare companies in the U.S., and previously served on the board of directors for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. Mr. Kazimi’s MBA is from the Owen Graduate School of Management at Vanderbilt University. |
 |
Joseph O. Rolwing, MBA, is Senior Director of the CET Life Sciences Center, having retired in 2010 from the concurrent position President and Executive Director of the Tennessee Biotechnology Association (now known as Life Science Tennessee). Mr. Rolwing’s 38 years of experience in the healthcare industry includes former positions as Vice President and Business Manager for Genetics Associates, Inc., a $3.2 million diagnostic medical lab, and Vice President of Corporate Affairs for Centerstone Community Mental Health Centers, Inc., where he managed care contracts, budgeting, risk management, billing and accounts receivable. Mr. Rolwing also served as Special Projects Director and Finance Director for the Helen Ross McNabb Center in Knoxville, Tennessee. His MBA is from the University of North Carolina-Chapel Hill. |
 |
Mohammad Amin Zarandi, Ph.D., is a Research Scientist at Cumberland Pharmaceuticals Inc., where he oversees the company’s formulation laboratories and supports Chemistry, Manufacturing, and Controls (CMC) activities for clinical and early-stage development programs. His responsibilities include leading formulation and analytical development, managing laboratory operations, contributing to grant applications, and collaborating on cross-functional research initiatives that advance the company’s product pipeline. Prior to joining Cumberland Pharmaceuticals, Dr. Zarandi served as a Graduate Research and Teaching Assistant at Tulane University. His research focused on the development and optimization of analytical methods, small-molecule synthesis, the design and construction of fluorophore-functionalized DNA nanostructures, and the conjugation of macrocyclic compounds to antibodies for diagnostic applications. In addition to his research, he taught undergraduate chemistry laboratories and mentored students in laboratory techniques and scientific research. Dr. Zarandi holds a Ph.D. in Organic Chemistry from Tulane University, a Master of Science in Polymer Engineering from the University of Tehran and a Bachelor of Science in Polymer Engineering from Amirkabir University of Technology. |